Litcius/Paper detail

Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via Toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study

Shihyun You, Jared L. Delahaye, Megan E. Ermler, Jennifer S. Singh, William Jordan, Avijit Ray, N. W. Galwey, Daren Austin, Dickens Theodore, Melanie Paff

2022Journal of Hepatology25 citationsDOI

Topics & Concepts

Toll-like receptorVirologyHepatitis B virusOligonucleotideToll-Like Receptor 9VirusMedicineInnate immune systemImmunologyBiologyImmune systemGeneGene expressionBiochemistryDNA methylationHepatitis B Virus StudiesHepatitis C virus researchHepatitis Viruses Studies and Epidemiology
Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via Toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study | Litcius